
    
      Subjects with acute pancreatitis who meet the inclusion and exclusion criteria for the study
      will be recruited. Subjects will be randomized to receive either Dabigatran 150mg daily for
      three days or standard treatment. Vital signs, CBC, inflammatory markers and BMP, and
      bleeding complications will be evaluated daily for the next 7 days of until discharge
      whichever is sooner.
    
  